{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:07:18Z","timestamp":1776704838771,"version":"3.51.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Critically ill patients often present with low serum iron levels or anemia. We evaluated the impact of iron levels and iron homeostasis on the efficacy and safety of cefiderocol, an iron-chelator siderophore cephalosporin, in patients with nosocomial pneumonia in a post hoc analysis of the randomized, double-blind, Phase 3 APEKS-NP study (NCT03032380). Patients with Gram-negative nosocomial pneumonia received cefiderocol 2\u00a0g, 3-h infusion, q8h, or high-dose, extended-infusion meropenem 2\u00a0g, 3-h infusion, q8h, for 7\u201314\u00a0days. Efficacy and safety parameters, including specific iron homeostasis parameters (i.e., hepcidin, iron, total iron binding capacity, transferrin saturation), were analyzed according to baseline iron levels. In the cefiderocol and meropenem arms, 79.1% (117\/148) and 83.3% (125\/150) randomized patients, respectively, had low baseline serum iron levels. Rates of 14-day (12.3% [14\/114] vs 11.6% [14\/121]) and 28-day all-cause mortality (20.5% [23\/112] vs 19.0% [23\/121]), clinical cure (63.2% [72\/114] vs 67.2% [82\/122]), and microbiological eradication (43.6% [41\/94] vs 48.1% [51\/106]) at test of cure were similar in cefiderocol vs meropenem arms, respectively. In the overall safety population, rates of anemia-related adverse events were similar (cefiderocol arm 18.2% [27\/148], meropenem arm 18.7% [28\/150]). Changes from baseline to test of cure in hepcidin, iron, total iron binding capacity, and transferrin saturation were similar between treatment arms. Cefiderocol treatment did not affect iron homeostasis, and its efficacy and safety were not influenced by baseline serum iron levels. Clinicaltrials.gov registration: NCT03032380. Date of registration: 26 January 2017.<\/jats:p>","DOI":"10.1007\/s10096-021-04399-9","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T13:02:48Z","timestamp":1642078968000},"page":"467-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study"],"prefix":"10.1007","volume":"41","author":[{"given":"Eric P.","family":"Skaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Echols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anju","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Portsmouth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"5","key":"4399_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.chom.2013.04.010","volume":"13","author":"JE Cassat","year":"2013","unstructured":"Cassat JE, Skaar EP (2013) Iron in infection and immunity. Cell Host Microbe 13(5):509\u2013519. https:\/\/doi.org\/10.1016\/j.chom.2013.04.010","journal-title":"Cell Host Microbe"},{"key":"4399_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1146\/annurev-genet-120215-035146","volume":"50","author":"LD Palmer","year":"2016","unstructured":"Palmer LD, Skaar EP (2016) Transition metals and virulence in bacteria. Annu Rev Genet 50:67\u201391. https:\/\/doi.org\/10.1146\/annurev-genet-120215-035146","journal-title":"Annu Rev Genet"},{"issue":"Suppl 7","key":"4399_CR3","doi-asserted-by":"publisher","first-page":"S529","DOI":"10.1093\/cid\/ciz825","volume":"69","author":"M Page","year":"2019","unstructured":"Page M (2019) The role of iron and siderophores in infection, and the development of siderophore antibiotics. Clin Infect Dis 69(Suppl 7):S529-537. https:\/\/doi.org\/10.1093\/cid\/ciz825","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4399_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ccc.2018.11.014","volume":"35","author":"LS Chawla","year":"2019","unstructured":"Chawla LS, Beers-Mulroy B, Tidmarsh GF (2019) Therapeutic opportunities for hepcidin in acute care medicine. Crit Care Clin 35(2):357\u2013374. https:\/\/doi.org\/10.1016\/j.ccc.2018.11.014","journal-title":"Crit Care Clin"},{"issue":"2","key":"4399_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00281-011-0294-4","volume":"34","author":"JE Cassat","year":"2012","unstructured":"Cassat JE, Skaar EP (2012) Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity. Semin Immunopathol 34(2):215\u2013235. https:\/\/doi.org\/10.1007\/s00281-011-0294-4","journal-title":"Semin Immunopathol"},{"issue":"6","key":"4399_CR6","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3390\/ijms21062145","volume":"21","author":"M Marchetti","year":"2021","unstructured":"Marchetti M, De Bei O, Bettati S, Campanini B, Kovachka S, Gianquinto E et al (2021) Iron metabolism at the interface between host and pathogen: from nutritional immunity to antibacterial development. Int J Mol Sci 21(6):2145. https:\/\/doi.org\/10.3390\/ijms21062145","journal-title":"Int J Mol Sci"},{"key":"4399_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.nutr.26.061505.111303","volume":"26","author":"E Nemeth","year":"2006","unstructured":"Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323\u2013342. https:\/\/doi.org\/10.1146\/annurev.nutr.26.061505.111303","journal-title":"Annu Rev Nutr"},{"issue":"9","key":"4399_CR8","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","volume":"108","author":"DM Wrighting","year":"2006","unstructured":"Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108(9):3204\u20133209. https:\/\/doi.org\/10.1182\/blood-2006-06-027631","journal-title":"Blood"},{"issue":"18","key":"4399_CR9","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.3390\/molecules24183314","volume":"24","author":"KH Negash","year":"2019","unstructured":"Negash KH, Norris JKS, Hodgkinson JT (2019) Siderophore-antibiotic conjugate design: new drugs for bad bugs? Molecules 24(18):3314. https:\/\/doi.org\/10.3390\/molecules24183314","journal-title":"Molecules"},{"issue":"1","key":"4399_CR10","doi-asserted-by":"publisher","first-page":"e01454","DOI":"10.1128\/aac.01454-17","volume":"62","author":"A Ito","year":"2017","unstructured":"Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S et al (2017) In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 62(1):e01454-e1517. https:\/\/doi.org\/10.1128\/aac.01454-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4399_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/s1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18(12):1319\u20131328. https:\/\/doi.org\/10.1016\/s1473-3099(18)30554-1","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"4399_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/s1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226\u2013240. https:\/\/doi.org\/10.1016\/s1473-3099(20)30796-9","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"4399_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS et al (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21(2):213\u2013225. https:\/\/doi.org\/10.1016\/s1473-3099(20)30731-3","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"4399_CR14","doi-asserted-by":"publisher","first-page":"S661","DOI":"10.1093\/ofid\/ofaa439.1475","volume":"7","author":"Y Matsunaga","year":"2020","unstructured":"Matsunaga Y, Sonoyama T, Casanova L, Nagata TD, Echols R, De Gregorio F et al (2020) Safety profile of the novel siderophore cephalosporin cefiderocol in randomized Phase 2 and Phase 3 clinical studies of serious Gram-negative infections. Open Forum Infect Dis 7(Suppl 1):S661-662. https:\/\/doi.org\/10.1093\/ofid\/ofaa439.1475","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"4399_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13054-018-2253-0","volume":"22","author":"S Lasocki","year":"2018","unstructured":"Lasocki S, Lefebvre T, Mayeur C, Puy H, Mebazaa A, Gayat A, FROG-ICU study group (2018) Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients. Crit Care 22(1):314. https:\/\/doi.org\/10.1186\/s13054-018-2253-0","journal-title":"Crit Care"},{"issue":"1","key":"4399_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000497123","volume":"47","author":"M Boshuizen","year":"2020","unstructured":"Boshuizen M, Binnekade JM, Nota B, van de Groep K, Cremer OL, Horn J et al (2020) Potential of parameters of iron metabolism for the diagnosis of anemia of inflammation in the critically ill. Transfus Med Hemother 47(1):61\u201367. https:\/\/doi.org\/10.1159\/000497123","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"4399_CR17","doi-asserted-by":"publisher","first-page":"e01961-19","DOI":"10.1128\/AAC.01961-19","volume":"64","author":"JM Kidd","year":"2019","unstructured":"Kidd JM, Abdelraouf K, Nicolau DP (2019) Development of neutropenic murine models of iron overload and depletion to study the efficacy of siderophore-antibiotic conjugates. Antimicrob Agents Chemother 64(1):e01961\u201319.\u00a0https:\/\/doi.org\/10.1128\/AAC.01961-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4399_CR18","doi-asserted-by":"publisher","unstructured":"Kidd JM, Abdelraouf K, Nicolau DP (2019) Efficacy of humanized cefiderocol exposure is unaltered by host iron overload in the thigh infection model. Antimicrob Agents Chemother 64(1):e01767\u201319. \nhttps:\/\/doi.org\/10.1128\/AAC.01767-19","DOI":"10.1128\/AAC.01767-19"},{"issue":"12","key":"4399_CR19","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.molmed.2016.10.005","volume":"22","author":"BR Wilson","year":"2016","unstructured":"Wilson BR, Bogdan AR, Miyazawa M, Hashimoto K, Tsuji Y (2016) Siderophores in iron metabolism: from mechanism to therapy potential. Trends Mol Med 22(12):1077\u20131090. https:\/\/doi.org\/10.1016\/j.molmed.2016.10.005","journal-title":"Trends Mol Med"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04399-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04399-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04399-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T13:14:13Z","timestamp":1644498853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04399-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4399"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04399-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"16 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by relevant institutional review boards or independent ethics committees at each participating study site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was provided by all patients or their legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YM, AM, and SP are employees of Shionogi Inc. EPS and RE are consultants for Shionogi and received consultancy fee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}